↓ Skip to main content

Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells

Overview of attention for article published in Journal of Translational Medicine, October 2011
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

twitter
8 X users
patent
2 patents
facebook
3 Facebook pages
googleplus
1 Google+ user

Citations

dimensions_citation
145 Dimensions

Readers on

mendeley
193 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells
Published in
Journal of Translational Medicine, October 2011
DOI 10.1186/1479-5876-9-181
Pubmed ID
Authors

Jeong Chan Ra, Sung Keun Kang, Il Seob Shin, Hyeong Geun Park, Sang Aun Joo, Jeong Geun Kim, Byeong-Cheol Kang, Yong Soon Lee, Ken Nakama, Min Piao, Bertram Sohl, Andras Kurtz

Abstract

Prolonged life expectancy, life style and environmental changes have caused a changing disease pattern in developed countries towards an increase of degenerative and autoimmune diseases. Stem cells have become a promising tool for their treatment by promoting tissue repair and protection from immune-attack associated damage. Patient-derived autologous stem cells present a safe option for this treatment since these will not induce immune rejection and thus multiple treatments are possible without any risk for allogenic sensitization, which may arise from allogenic stem cell transplantations. Here we report the outcome of treatments with culture expanded human adipose-derived mesenchymal stem cells (hAdMSCs) of 10 patients with autoimmune associated tissue damage and exhausted therapeutic options, including autoimmune hearing loss, multiple sclerosis, polymyotitis, atopic dermatitis and rheumatoid arthritis. For treatment, we developed a standardized culture-expansion protocol for hAdMSCs from minimal amounts of fat tissue, providing sufficient number of cells for repetitive injections. High expansion efficiencies were routinely achieved from autoimmune patients and from elderly donors without measurable loss in safety profile, genetic stability, vitality and differentiation potency, migration and homing characteristics. Although the conclusions that can be drawn from the compassionate use treatments in terms of therapeutic efficacy are only preliminary, the data provide convincing evidence for safety and therapeutic properties of systemically administered AdMSC in human patients with no other treatment options. The authors believe that ex-vivo-expanded autologous AdMSCs provide a promising alternative for treating autoimmune diseases. Further clinical studies are needed that take into account the results obtained from case studies as those presented here.

X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 193 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 5 3%
Japan 2 1%
Netherlands 1 <1%
Germany 1 <1%
France 1 <1%
Unknown 183 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 42 22%
Student > Master 27 14%
Student > Ph. D. Student 22 11%
Student > Bachelor 19 10%
Other 12 6%
Other 33 17%
Unknown 38 20%
Readers by discipline Count As %
Medicine and Dentistry 53 27%
Agricultural and Biological Sciences 45 23%
Biochemistry, Genetics and Molecular Biology 20 10%
Nursing and Health Professions 7 4%
Engineering 6 3%
Other 20 10%
Unknown 42 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 December 2019.
All research outputs
#2,778,803
of 22,655,397 outputs
Outputs from Journal of Translational Medicine
#438
of 3,950 outputs
Outputs of similar age
#15,447
of 139,967 outputs
Outputs of similar age from Journal of Translational Medicine
#3
of 46 outputs
Altmetric has tracked 22,655,397 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,950 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.4. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 139,967 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.